Core Viewpoint - The innovative pharmaceutical sector has emerged as the "most shining track" in the capital market for the first half of 2025, with the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index achieving a year-to-date increase of 97.01%, marking the highest half-year growth since 2018 [1] Group 1: Company Performance - By the first half of 2025, the company reported revenue exceeding RMB 6 billion, a year-on-year increase of over 50%, and net profit ranging from RMB 42.7 million to RMB 52.7 million, marking a continuous profit validation [1][3] - The company's stock price surged by 209.88% year-to-date, outperforming both the Hang Seng Healthcare Index and the Hang Seng Index [1] Group 2: Strategic Transformation - The company has transitioned its revenue structure from "service infusion" to "product self-sustenance," indicating a successful shift towards high-value products and validating the commercial viability of its technology [3] - The company has established a global presence, enhancing its local service capabilities through the expansion of its Boston laboratory and securing collaborations with top 10 multinational pharmaceutical companies [4] Group 3: Operational Efficiency - The company increased its R&D expenditure to approximately RMB 206.1 million to RMB 216.1 million, a year-on-year increase of about 30%, while optimizing its management structure and digitalizing production processes to enhance operational efficiency [5] - The company achieved net profit for two consecutive reporting periods, indicating the establishment of a commercial flywheel effect from R&D investment to product revenue and profit accumulation [5] Group 4: Market Opportunities - Recent policy measures from the National Healthcare Security Administration and the National Health Commission support the high-quality development of innovative drugs, creating a favorable environment for companies like the subject firm [6] - The capital market's evaluation logic for innovative pharmaceutical companies has fundamentally changed, with a shift from "story-driven" to "performance-driven" valuation, enhancing confidence in profitability [7] Group 5: Globalization and Future Growth - The company is positioned as a significant contributor to the global pharmaceutical pipeline, particularly in the ADC (antibody-drug conjugate) field, and ranks among the top three in terms of outbound licensing transactions [8] - The company's unique technology platforms and innovative antibody assets are expected to establish it as a "technical arms dealer" in the global pharmaceutical landscape, potentially leading to a dual growth trajectory [8] Conclusion - The company is poised for a significant transformation from a follower to a leader in the global innovative drug sector, with its recent profitability breakthrough marking just the beginning of its growth journey [9][10]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 百奧賽圖(北京)醫藥科技股份有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02315 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 110,781,920 | RMB | | 1 RMB | | 110,781,920 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類 ...

本文源自：财华网 【财华社讯】百奥赛图-B(02315.HK)公布，预计截至2025年6月30日止六个月，营业收入约为6.16亿元 至6.26亿元(人民币,下同)，同比增加约50.1%至52.5%；净利润约4270万元至5270万元，同比扭亏为盈， 相较2024年同期为亏损5070万元。年研发费用约2.06亿元至2.16亿元，同比增加约27.5%至33.6%。 ...

Core Viewpoint - 百奥赛图-B (02315) reported a significant increase in revenue and profitability for the first half of 2025, driven by innovation, market expansion, and optimized management strategies [1] Financial Performance - The company expects revenue for the first half of 2025 to reach between RMB 616 million and RMB 626 million, representing a year-on-year growth of approximately 50.1% to 52.5% [1] - Research and development expenses are projected to be between RMB 206.1 million and RMB 216.1 million, reflecting a year-on-year increase of about 27.5% to 33.6% [1] - The anticipated net profit is between RMB 42.7 million and RMB 52.7 million, indicating a turnaround from previous losses [1] Market Expansion - The company has strengthened its overseas market presence by expanding its sales team and improving its sales system, leading to rapid growth in international business [1] - The release of R&D demand from domestic biopharmaceutical companies has provided development opportunities, particularly in preclinical products and services [1] Technological Edge - 百奥赛图 has established a strong technological barrier with its unique gene editing technology and animal model platform, focusing on over 20 key disease areas and thousands of high-value target models [3] - The company serves nearly 900 pharmaceutical and research institutions globally, completing over 5,300 drug evaluation projects, which supports its preclinical products and services business [3] Diversified Revenue Streams - The antibody licensing and development business is supported by the RenMice platform, which has created a resource library of over one million fully human antibody molecules [4] - By the end of 2024, the company has established around 200 cooperation agreements with various domestic and international pharmaceutical companies, with over 50 licensed projects covering multiple innovative targets [4] - The ongoing expansion of clinical pre-service scale and growth in antibody licensing business is expected to enhance the company's value in the innovative drug industry chain [4]

Core Viewpoint - Baiaosaitu-B (02315) reported a significant increase in revenue and profitability for the first half of 2025, driven by innovation, market expansion, and optimized management strategies [1] Financial Performance - The company expects revenue for the first half of 2025 to reach between RMB 616 million and RMB 626 million, representing a year-on-year growth of approximately 50.1% to 52.5% [1] - Research and development expenses are projected to be between RMB 206.1 million and RMB 216.1 million, reflecting a year-on-year increase of about 27.5% to 33.6% [1] - The anticipated net profit is between RMB 42.7 million and RMB 52.7 million, indicating a turnaround from losses to profitability [1] Strategic Initiatives - The company has maintained a high level of R&D investment and dynamically adjusted its R&D focus based on business development needs [1] - Baiaosaitu has strengthened its overseas market presence by expanding its sales team and improving its sales system, leading to rapid growth in international business [1] - The release of R&D demand from domestic biopharmaceutical companies has created opportunities for Baiaosaitu, particularly in preclinical products and services [1] Market Performance - The stock price of Baiaosaitu has surged nearly 300% from a low of HKD 5.6 in late November last year to HKD 21.45 as of July 28, significantly outperforming the Hang Seng Index and Hang Seng Tech Index [2] Core Technology and Business Growth - Baiaosaitu has established a strong technological barrier with its unique gene editing technology and animal model platform, focusing on over 20 key disease areas [3] - The company has developed thousands of high-value target models, serving nearly 900 pharmaceutical and research institutions globally, completing over 5,300 drug evaluation projects [3] Revenue Diversification - The antibody licensing and development business is supported by the RenMice® platform, which has created a resource library of over one million fully human antibody molecules [4] - By the end of 2024, Baiaosaitu has established around 200 cooperation agreements with various domestic and international pharmaceutical companies, with over 50 licensed projects [4] - The ongoing expansion of clinical pre-service scale and growth in antibody licensing business is expected to enhance the company's value in the innovative drug industry chain [4]

Core Viewpoint - The company, Baiaosaitu-B (02315.HK), is expected to report significant growth in revenue and profitability for the first half of 2025, driven by strategic innovation and market expansion efforts [1][2]. Group 1: Financial Performance - The estimated revenue for the six months ending June 30, 2025, is approximately RMB 616 million to RMB 626 million, representing a year-on-year increase of about 50.1% to 52.5% [1]. - The expected net profit is around RMB 42.7 million to RMB 52.7 million, indicating a turnaround from loss to profit [1]. - Research and development expenses are projected to be between RMB 206.1 million and RMB 216.1 million, reflecting a year-on-year increase of approximately 27.5% to 33.6% [1]. Group 2: Growth Drivers - The company attributes its strong performance to its strategic focus on "driving new drug development through innovative technology," aiming to become a global source of new drugs while maintaining a strong presence in China [2]. - In the first half of 2025, the company has intensified its efforts in overseas market expansion, supported by an expanding sales team and improved sales systems, leading to rapid growth in international business [2]. - The domestic biopharmaceutical sector has seen increased R&D demand, allowing the company to provide innovative R&D products and services that meet customer needs, resulting in robust growth in domestic operations [2]. Group 3: Operational Efficiency - The company is implementing lean management practices, adjusting and optimizing its management team to enhance operational efficiency, which has led to a continuous decline in management expense ratios [2]. - By reorganizing R&D and production activities more effectively, the company has improved the efficiency of human resource utilization, facilitating a smoother transition from innovative R&D to commercial production [2]. - These ongoing initiatives have significantly enhanced the company's profitability [2].

Core Viewpoint - The company expects significant revenue growth and profitability improvement in the first half of 2025, driven by overseas market expansion and domestic business growth [1] Financial Performance - Projected revenue for the first half of 2025 is approximately between 616 million to 626 million yuan, representing a year-on-year increase of about 50.1% to 52.5% [1] - Expected net profit is estimated to be between 42.7 million to 52.7 million yuan, indicating a turnaround from previous losses [1] - Anticipated R&D expenses are projected to be between 206 million to 216 million yuan, reflecting a year-on-year increase of approximately 27.5% to 33.6% [1] Growth Drivers - The performance growth is primarily attributed to the company's ongoing efforts in expanding overseas markets and enhancing domestic business operations [1] - Implementation of lean management practices is expected to further improve profitability [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. 百奧賽圖（北京）醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2315） 截至2025年6月30日止六個月業績快報 本公告乃由百奧賽圖（北京）醫藥科技股份有限公司（「本公司」）根據香港法例第 571章證券及期貨條例第XIVA部項下內幕消息條文（定義見香港聯合交易所有限 公司證券上市規則（「上市規則」））及上市規則第13.09條而作出。 本公告所載本公司及其附屬公司（統稱「本集團」）截至2025年6月30日止六個月的 主要財務數據為根據國際財務報告準則所做之初步財務數據，未經本公司核數師 審計，因此本公告所述之財務數據與本集團截至2025年6月30日止六個月中期業 績公告中披露的數據可能存在差異，最終中期數據以後者披露的數據為準，謹此 提請投資者注意投資風險。 I. 本期業績預告情 ...

Core Viewpoint - The stock of Baiaosaitu-B (02315) surged over 10% following the announcement of a global licensing agreement for antibody molecules with BeiGene, indicating strong market confidence in the company's growth prospects and collaboration with established partners [1] Company Developments - Baiaosaitu has entered into a global licensing agreement with BeiGene, which includes an upfront payment and potential milestone payments based on development and commercialization, as well as royalties based on net sales [1] - The collaboration builds on an existing relationship where BeiGene had previously obtained a license for Baiaosaitu's RenMice fully human antibody platform, reflecting a deepening partnership [1] Financial Performance - Dongwu Securities reported that Baiaosaitu's operational performance in the first half of the year exceeded expectations, with significant growth in business development (BD) activities [1] - The company is expected to achieve over 40% growth in its antibody BD business and maintain over 40% growth in animal models, with preclinical CRO growth nearing 60%, leading to an overall revenue growth exceeding 40% [1]

Core Viewpoint - 百奥赛图-B (02315) has seen a significant increase in stock price following the announcement of a global licensing agreement with BeiGene for antibody molecules, indicating strong market confidence in the company's growth prospects [1] Group 1: Licensing Agreement - 百奥赛图 has entered into a global licensing agreement with BeiGene for antibody molecules, which includes an upfront payment and potential milestone payments based on development and commercialization [1] - The agreement builds on an existing collaboration where BeiGene had previously obtained a license for 百奥赛图's RenMice fully human antibody platform, indicating a deepening partnership [1] Group 2: Financial Performance - 东吴证券 reported that 百奥赛图's operating performance in the first half of the year exceeded expectations, with business development (BD) continuing to grow [1] - The company is expected to achieve over 40% growth in its antibody BD business in the first half of 2025, with animal models maintaining over 40% growth and preclinical CRO growth nearing 60% [1] - Overall revenue growth for 百奥赛图 is projected to exceed 40%, supported by a recovery in domestic industrial clients and a rapid increase in orders [1]